AstraZeneca Reports Positive Results From Phase III Trial With Datopotamab Deruxtecan

(RTTNews) - AstraZeneca PLC (AZN.L, AZN) said high-level results from the TROPION-Breast01 Phase III trial with datopotamab deruxtecan showed a statistically significant and clinically meaningful improvement for the primary endpoint of progression-free survival compared to invest https://www.nasdaq.com/articles/astrazeneca-reports-positive-results-from-phase-iii-trial-with-datopotamab-deruxtecan